A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects: the ScanSmart Study.

Trial Profile

A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects: the ScanSmart Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2012

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms SCANSMART
  • Sponsors Merck KGaA
  • Most Recent Events

    • 11 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2011 Planned end date changed from 1 Nov 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 13 Dec 2010 Actual initiation date (Sep 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top